Professor Juergen Reichardt
K25 - Medical Foundation Building
The University of Sydney NSW 2006 Australia |
|
||||||||
As human geneticists and biochemists we wish to understand how the human genome in conjunction with the environment produces the multitude of human phenotypes. We are particularly interested in the contribution of human genetic variation to common, complex significant public health problems. We also have an interest in understanding the genetics of human metabolism and genetic variation thereof.
This laboratory has a longstanding tradition of characterizing human galactose-metabolic enzymes and associated diseases. We are currently also investigating two complex disease phenotypes with significant public health impact: various cancers and heart disease. Our strategy is to dissect these diseases through a step-wise, candidate gene approach. Our systematic choice of candidate genes for these diseases was dictated by the hypothesized involvement of particular metabolic pathways in pathogenesis. In prostate cancer we are currently investigating three androgen metabolic genes since androgens have been reported to regulate cell division in the prostate. We have focused on the steroid 5α-reductase type II (SRD5A2) locus and are currently exploring also the HSD3B2 and HSD17B3 genes. Investigations into colon cancer and atherosclerosis are also under way.
This laboratory has a longstanding tradition of characterizing human galactose-metabolic enzymes and associated diseases. We are currently also investigating two complex disease phenotypes with significant public health impact: various cancers and heart disease. Our strategy is to dissect these diseases through a step-wise, candidate gene approach. Our systematic choice of candidate genes for these diseases was dictated by the hypothesized involvement of particular metabolic pathways in pathogenesis. In prostate cancer we are currently investigating three androgen metabolic genes since androgens have been reported to regulate cell division in the prostate. We have focused on the steroid 5α-reductase type II (SRD5A2) locus and are currently exploring also the HSD3B2 and HSD17B3 genes. Investigations into colon cancer and atherosclerosis are also under way.
Current national competitive grants
|
2005 |
|
|
Biology Of Prostate Cancer Prevention Trial (PCPT) |
|
| National Institutes of Health (USA) Research Support | $286,877 over 5 years |
2010
- Flanagan, J, McMahon, G, Brendan Chia, S, Fitzpatrick, P, Tighe, O, O'Neill, C, Briones, P, Gort, L, Kozak, L, Magee, A, Naughten, E, Radomyska, B, Schwartz, M, Shin, J, Strobl, W, Tyfield, L, Waterham, H, Russell, H, Bertorelle, G, Reichardt, J, Mayne, P, Croke, D. The role of human demographic history in determining the distribution and frequency of transferase-deficient galactosaemia mutations. Heredity. 2010; 104:148-54
- Musumeci, L, Arthur, J, Cheung, F, Hoque, A, Lippman, S, Reichardt, J. Single Nucleotide Differences (SNDs) in the dbSNP Database May Lead to Errors in Genotyping and Haplotyping Studies. Human Mutation. 2010; 31:67-73
2009
- Makridakis, N, Phipps, T, Srivastav, S, Reichardt, J. PCR-free method detects high frequency of genomic instability in prostate cancer. Nucleic acids research. 2009; 37:7441-6
- Makridakis, N, Caldas Ferraz, L, Reichardt, J. Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. Human mutation. 2009; 30:39-48
2008
- Pearce, C, Van Den Berg, D, Makridakis, N, Reichardt, J, Ross, R, Pike, M, Kolonel, L, Henderson, B. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Human molecular genetics. 2008; 17:2456-2461
- Shai, R, Reichardt, J, Chen, T. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future oncology. 2008; 4:525-534
- Chu, L, Reichardt, J, Hsing, A. Androgens and the molecular epidemiology of prostate cancer. Current opinion in endocrinology, diabetes, and obesity. 2008; 15:261-270
- Reichardt, J. Realizing the full potential of the sequenced human genome. Trends in Genetics. 2008. p. 219-220.
2007
- Reichardt, J. Quo vadis, genoma? A call to pipettes for biochemists. Trends in biochemical sciences. 2007. p. 529-30.
- D'Amico, F, Biancolella, M, Margiotti, K, Reichardt, J, Novelli, G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics. 2007; 8:645-661
- Reichardt, J, Tilley, W. The 3rd Pacific Rim meeting on breast and prostate cancer: progress in hormonal carcinogenesis and the enduring influence of Ron Ross. Cancer research. 2007; 67:4550-4552
- Mehrian-Shai, R, Chen, C, Shi, T, Horvath, S, Nelson, S, Reichardt, J, Sawyers, C. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:5563-5568
- Chokkalingam, A, Stanczyk, F, Reichardt, J, Hsing, A. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Frontiers in bioscience : a journal and virtual library. 2007; 12:3436-3460
2006
- Reichardt, J. Unexpected biochemical and pharmacogenetic consequences of SNPs and haplotypes: a cautionary tale for human molecular genetics and epidemiology. Genomics. 2006. p. 673-4.
- Mehrian-Shai, R, Reichardt, J. Genomics in breast and prostate cancer: assessment of the current state and future perspectives. Future oncology (London, England). 2006; 2:357-62
2005
- Makridakis, N, Buchanan, G, Tilley, W, Reichardt, J. Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in bioscience : a journal and virtual library. 2005; 10:2892-903
- Makridakis, N, Reichardt, J. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. Journal of molecular endocrinology. 2005; 34:617-23
- Mehrian Shai, R, Reichardt, J, Ya-Hsuan, H, Kremen, T, Liau, L, Cloughesy, T, Mischel, P, Nelson, S. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain research. Molecular brain research. 2005; 136:99-103
- Salam, M, Ursin, G, Skinner, E, Dessissa, T, Reichardt, J. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urologic oncology. 2005; 23:246-53
2004
- Makridakis, N, Akalu, A, Reichardt, J. Identification and characterization of somatic steroid 5 alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene. 2004; 23:7399-7405
- Foti, D, Reichardt, J. YY1 binding within the human HSD3132 gene intron 1 is required for maximal basal promoter activity: Identification of YY1 as the 3 beta 1-A factor. Journal of Molecular Endocrinology. 2004; 33:99-119
- Novelli, G, Margiotti, K, Chiocca, A, Spera, E, Micali, F, Reichardt, J. Pharmacogenetics of human androgens and prostate cancer - an update. Pharmacogenomics. 2004; 5:283-294
- Reichardt, J. Molecular genetics of common human diseases including prostate cancer. Cancer Epidemiology Biomarkers & Prevention. 2004; 13:1961S-1962S
- Mehrian-Shai, R, Reichardt, J. A renaissance of. haplotypes. 2004; function:Molecular Genetics and Metabolism
2003
- Makridakis, N, Ferraz, L, Reichardt, J. Most somatic mutations in human prostate cancer tissue conform to a specific motif. American Journal of Human Genetics. 2003; 73:228-228
- Salam, M, Ursin, G, Skinner, E, Dessissa, T, Reichardt, J. Associations between polymorphisms in the steroid 5 alpha-reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. American Journal of Human Genetics. 2003; 73:374-374
- Kobayashi, K, Lu, Y, Li, M, Nishi, I, Hsiao, K, Choeh, K, Yang, Y, Hwu, W, Reichardt, J, Palmieri, F, Okano, Y, Saheki, T. Screening of nine SLC25A13 mutations: their frequency in patients with citrin deficiency and high carrier rates in Asian populations. Molecular Genetics and Metabolism. 2003; 80:356-359
- Allen, N, Reichardt, J, Nguyen, H, Key, T. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiology Biomarkers & Prevention. 2003; 12:578-581
2002
- Goodman, M, Wu, A, Tung, K, McDuffie, K, Cramer, D, Wilkens, L, Terada, K, Reichardt, J, Ng, W. Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer. American Journal of Epidemiology. 2002; 156:693-701
- Margiotti, K, Kim, E, Pearce, C, Spera, E, Novelli, G, Reichardt, J. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate. 2002; 53:65-68
- Salam, M, Reichardt, J, Skinner, E, Paz, L, Ursin, G. Association between body mass and benign prostatic hyperplasia. American Journal of Epidemiology. 2002; 155:s80-s80
- Pearce, C, Makridakis, N, Ross, R, Pike, M, Kolonel, L, Henderson, B, Reichardt, J. Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiology Biomarkers & Prevention. 2002; 11:417-418
- Cozen, W, Peters, R, Reichardt, J, Ng, W, Felix, J, Wan, P, Pike, M. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes & Control. 2002; 13:113-120
2001
- Makridakis, N, Reichardt, J. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiologic Reviews. 2001; 23:24-29
- Okano, Y, Asada, M, Fujimoto, A, Ohtake, A, Murayama, K, Hsiao, K, Choeh, K, Yang, Y, Cao, Q, Reichardt, J, Niihira, S, Imamura, T, Yamano, T. A genetic factor for age-related cataract: Identification and characterization of a novel galactokinase variant,. . 2001; American Journal of Human Genetics:4
- Novelli, G, Margiotti, K, Sangiuolo, F, Reichardt, J. Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics. 2001; 2:65-72
- Makridakis, N, Reichardt, J. Multiplex automated primer extension analysis: Simultaneous genotyping of several polymorphisms. Biotechniques. 2001; 31:1374-1380
- Hsing, A, Chen, C, Chokkalingam, A, Gao, Y, Dightman, D, Nguyen, H, Deng, J, Cheng, J, Sesterhenn, I, Mostofi, F, Stanczyk, F, Reichardt, J. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiology Biomarkers & Prevention. 2001; 10:1077-1082
2000
- Margiotti, K, Sangiuolo, F, De Luca, A, Froio, F, Pearce, C, Ricci-Barbini, V, Micali, F, Bonafe, M, Franceschi, C, Dallapiccola, B, Novelli, G, Reichardt, J. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Disease Markers. 2000; 16:147-150
- Makridakis, N, Reichardt, J. Biochemical characterization of SRD5A2 gene polymorphisms found in Benign Prostatic Hyperplasia (BPH) patients. American Journal of Human Genetics. 2000; 67:284-284
- Novelli, G, Reichardt, J. Molecular basis of disorders of human galactose metabolism: Past, present, and future. Molecular Genetics and Metabolism. 2000; 71:62-65
- Makridakis, N, di Salle, E, Reichardt, J. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics. 2000; 10:407-413
1999
- Akalu, A, Reichardt, J. A reliable PCR amplification method for microdissected tumor cells obtained from paraffin-embedded tissue. Genetic Analysis-Biomolecular Engineering. 1999; 15:229-233
- Makridakis, N, Ross, R, Pike, M, Crocitto, L, Kolonel, L, Pearce, C, Henderson, B, Reichardt, J. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999; 354:975-978
- Ross, R, Coetzee, G, Pearce, C, Reichardt, J, Bretsky, P, Kolonel, L, Henderson, B, Lander, E, Altshuler, D, Daley, G. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. European Urology. 1999; 35:355-361
- Akalu, A, Elmajian, D, Highshaw, R, Nichols, P, Reichardt, J. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5 alpha-reductase during prostate cancer progression. Journal of Urology. 1999; 161:1355-1358
